Affinia Therapeutics CEO to Attend Notable Health Conferences
Affinia Therapeutics to Participate in Key Industry Events
Affinia Therapeutics, a leader in gene therapy innovation, is set to participate in a couple of prominent investor and industry conferences. These events are an excellent opportunity for them to showcase their advancements in rationally designed therapies aimed at addressing rare and prevalent diseases.
Details of the Upcoming Conferences
Rick Modi, the CEO of Affinia Therapeutics, will take part in significant discussions at two major conferences scheduled for the upcoming weeks. Each conference will allow for an engaging exchange of ideas regarding the development of innovative gene therapies.
Chardan's 8th Annual Genetic Medicines Conference
This conference will occur from September 30 to October 1, featuring panel discussions on the engineering of adeno-associated viruses (AAVs). Affinia's participation will include:
- Format: Panel titled 'Engineering of AAVs – The Promise of Next Gen AAVs' and a corporate presentation.
- Date: September 30.
- Time: 9:30 AM EDT for the panel and a presentation at 10:30 AM EDT.
Cell & Gene Meeting on the Mesa
Following on, from October 7 to 9, Affinia will also participate in the Cell & Gene Meeting on the Mesa. This conference will focus on next-generation gene therapies and will include:
- Format: Corporate presentations and a panel on improving efficiencies in CGT process development.
- Date: October 8.
- Time: A corporate presentation at 10:00 AM MST (1:00 PM EDT) followed by a panel at 4:15 PM MST (7:15 PM EDT).
One-on-One Meetings
In addition to the panel discussions, members of Affinia's management team will be on hand at both conferences to engage in one-on-one meetings, providing a great opportunity for personalized discussions about their innovative approaches in gene therapy.
About Affinia Therapeutics
Affinia Therapeutics is at the forefront of the shift toward rationally designed gene therapies, with a proprietary platform focusing on improving the efficacy, safety, and manufacturability of AAV-based treatments. Their pipeline addresses cardiovascular and neurological conditions, making strides towards enhancing health outcomes.
Frequently Asked Questions
What is Affinia Therapeutics known for?
Affinia Therapeutics is recognized for its innovative gene therapy solutions targeting rare and prevalent diseases.
Who is leading Affinia Therapeutics?
The company is led by CEO Rick Modi, who actively participates in significant health conferences.
What will be discussed at the upcoming conferences?
The conferences will cover advancements in gene therapies, focusing on improving AAV engineering and the next generation of CGT process development.
Where can I find more information about Affinia?
For more insights into their work and updates, check Affinia's official website.
How can I attend the one-on-one meetings with Affinia's management?
Interested parties can arrange meetings during the conferences by contacting Affinia's management team directly at the events.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Evolus Expands Stock Incentives to New Non-Executive Roles
- Cresco Labs Board of Directors Sees Recent Changes
- Legal Action Announced for Metagenomi Investors – Key Details
- Understanding Your Rights as an Allarity Therapeutics Investor
- Investors Urged to Explore Legal Action Against Flux Power
- Metagenomi, Inc. Investors File Class Action Under SEC Laws
- Investigation Launched Into Acadia Healthcare Company: Insights
- Stellantis N.V. Investors Urged to Act Before Key Deadline
- China's Shift to Local AI Chips and Impacts on Nvidia
- Robbins LLP Urges Coinbase Global Investors to Act Now for Returns
Recent Articles
- Shareholders of Thoughtworks Urged to Explore Sale Options
- Sphere 3D's Mining Output Declines: A New Era Ahead
- Schneider Electric and Kimberly-Clark Partner for Renewable Energy
- Sustainable Markets Initiative Engages Leaders for Climate Action
- Elevation Oncology's EO-3021 Receives Fast Track FDA Designation
- Scotiabank Boosts Welltower Price Target After Investment Tour
- Comtech Telecommunications Corp Faces Leadership Shake-Up Ahead
- Biohaven's Troriluzole Offers Hope for SCA Patients
- Mativ Holdings Launches $400 Million Senior Notes Initiative
- Nike Experiences Caution from JPMorgan Before Earnings Release
- Market Movers: Key Stocks Rise and Fall Prior to Opening
- Volkswagen's CEO Calls for Major Union Concessions Amid Challenges
- Bitfarms and Riot Platforms: A Strategic Alliance Emerges
- Exploring E-Mini S&P 500 Futures: Key Trends for Traders
- Nvidia's Potential: Analyzing Future Growth and Challenges
- Discover Four Resilient Dividend Stocks Worth Considering
- Prospective Growth of Palantir Technologies and SoFi
- Navigating RMDs for Inherited 401(k) Plans With Care
- IDEX Biometrics General Meeting Highlights and Future Plans
- Alterity Therapeutics Discusses Phase 2 Trials at Key Conference
- Arrowhead Pharmaceuticals Seeks Approval for ARO-INHBE Trials
- Enhancing Event Management with Everbridge 360 Alert Tools
- Windstream Unveils Senior Notes Offering for Strategic Growth
- Harvest High Income Shares ETFs Announce Exciting Updates
- Bowman Wins IDOT Contract for I-55 Corridor Improvements
- Harvest Portfolios Group Announces Distributions for Investors
- Harvest ETFs Announce Upcoming Distributions for Investors
- Mural Oncology Welcomes Sachiyo Minegishi to Leadership Team
- Armanino Foods Elevates Presence with OTCQX Market Transition
- Explore Key Highlights from the Canadian Emergency Preparedness Events
- Leadership Upgrade: Jérôme Bichut Becomes Boyden Partner
- Aileron Therapeutics Advances LTI-03 Trial for Lung Disease
- Priovant Therapeutics Begins Phase 3 Study for Brepocitinib
- Elevation Oncology's EO-3021 Gains FDA Fast Track Approval
- Impressive Gold Intersections Reported by Nevada King Corp.
- Embr Labs: A Leader in Women's Health Digital Solutions
- Biohaven's Troriluzole Shows Promise in Treating SCA
- Former CEOs of Comtech Propose Board Candidates for Change
- Exploring Qualcomm's Relationship with Intel: Insights from Citi
- PayPal's New Strategies: What Investors Should Know About PYPL
- Apple's iPhone 16 Lead Times Indicate Shifting Demand Patterns
- Zapper Expands Horizons by Integrating with Moonbeam Network
- Revitalizing Returns: The Pfizer and Moderna Potential
- Market Anticipation: Fed Insights and Corporate Developments
- NorthWest Copper Completes Successful Private Placement Financing
- Employ Inc. Welcomes Joey Humke as New Chief Revenue Officer
- Brookfield Secures $2.4 Billion for Climate Fund Initiative
- Passage Bio's Upcoming Presentation at Genetic Medicines Conference
- Bitfarms and Riot Forge New Agreement to Enhance Governance
- Tonix Pharmaceuticals Presents Promising TNX-102 SL Data